Karyopharm Therapeutics Inc.
6.08-0.28 (-4.48%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · KPTI · USD
Key Stats
Market Cap
96.84MP/E (TTM)
-Basic EPS (TTM)
-14.84Dividend Yield
0%Recent Filings
8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2025 Karyopharm Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36167 26-3931704 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 85 Wells Avenue, 2nd Floor Newton, Massachusetts 02459 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (617) 658-0600 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act (17 CFR 240.14d-2) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter). ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act (§240.13a-15(f)). ☐ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter). ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act (§240.13a-15(f)). ☐ Item 1.01 Entry into a Material Definitive Agreement. On October 10, 2025, Karyopharm Therapeutics Inc. (the “Company”) entered into a First Amendment to Credit and Guaranty Agreement (the “First Amendment”), which amended that certain Credit and Guaranty Agreement, dated as of May 8, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among the Company, as borrower, the guarantors party thereto, the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (in such capacities, the “Agent”). The First Amendment provides for, among other things, (i) the incurrence of additional term loans in an aggregate principal amount of $12.5 million (the “Additional Term Loans”), (ii) the extension of the maturity date of the existing term loans under the Credit Agreement from May 8, 2028 to October 10, 2029, (iii) the extension of the maturity date of the existing revolving loans under the Credit Agreement from May 8, 2026 to October 10, 2027, and (iv) the incurrence of additional revolving loans in an aggregate principal amount of up to $5.0 million. The First Amendment also provides for an increase in the interest rate margin applicable to the Additional Term Loans and the additional revolving loans. The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the First Amendment, a copy of which is attached hereto as Exhibit 10.1. Item 1.02 Termination of a Material Definitive Agreement. None. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03. Item 3.02 Unregistered Sales of Equity Securities. None. Item 3.03 Material Modifications to Rights of Security Holders. None. Item 4.01 Changes in Registrant’s Certifying Accountant. None. Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. None. Item 5.01 Changes in Control of Registrant. None. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. None. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. None. Item 5.04 Temporary Suspension of Trading Under Registrant’s Debtor Name. None. Item 5.05 Other Events. None. Item 5.06 Resignations of Registrant’s Principal Officers. None. Item 5.07 Exemption from Registration Pursuant to Rule 477. None. Item 5.08 Other Events. On October 10, 2025, the Company entered into a First Amendment to Credit and Guaranty Agreement (the “First Amendment”), which amended that certain Credit and Guaranty Agreement, dated as of May 8, 2024 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), by and among the Company, as borrower, the guarantors party thereto, the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (in such capacities, the “Agent”). The First Amendment provides for, among other things, (i) the incurrence of additional term loans in an aggregate principal amount of $12.5 million (the “Additional Term Loans”), (ii) the extension of the maturity date of the existing term loans under the Credit Agreement from May 8, 2028 to October 10, 2029, (iii) the extension of the maturity date of the existing revolving loans under the Credit Agreement from May 8, 2026 to October 10, 2027, and (iv) the incurrence of additional revolving loans in an aggregate principal amount of up to $5.0 million. The First Amendment also provides for an increase in the interest rate margin applicable to the Additional Term Loans and the additional revolving loans. The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the First Amendment, a copy of which is attached hereto as Exhibit 10.1. Item 5.09 Other Events. None. Item 5.10 Other Events. None. Item 5.11 Insurance and Indemnification. None. Item 5.12 Disclosure of Securities Subject to Rule 16a-3. None. Item 5.13 Financial Statements and Exhibits. (d) Exhibits. Exhibit 10.1 First Amendment to Credit and Guarant...
The filing is a Form 8-K current report filed by Karyopharm Therapeutics Inc. on October 10, 2025, disclosing a series of refinancing transactions collectively referred to as the Sixth Amendment Transactions. These transactions include amendments to existing credit agreements, exchanges of convertible notes, issuance of new securities, and related agreements aimed at recapitalizing the company's capital structure. The report details the entry into a First Amendment to Credit and Guaranty Agreement, various exchange agreements for convertible notes, amendments to a revenue interest financing agreement, and securities purchase agreements. It also includes exhibits such as the amended credit agreement, exchange agreements, and registration rights agreements. The transactions involve multiple parties, including lenders and investors, and are structured to provide financial flexibility and support for the company's operations.
8-K
Board member resigns abruptly
Karyopharm Therapeutics' board member Mansoor Raza Mirza, M.D., resigned effective September 8, 2025, citing competing professional demands rather than any disputes over operations or policies. He steps away to take a new industry executive role, also ending his Chief Oncologist position at Copenhagen University National Medical Center by October 1. The company simultaneously terminated its consulting agreement with Mirza Consulting, his wholly-owned entity. No board replacement disclosed yet.
10-Q
Q2 FY2025 results
Karyopharm Therapeutics posted Q2 revenue of $37.9M, down 11% y/y but up 3% q/q (derived), with product sales edging up 6% y/y to $29.7M on lower 340B discounts, while license revenue dipped 44% y/y to $8.2M sans prior milestones. Operating loss narrowed 13% y/y to $24.4M as R&D fell 15% y/y to $32.8M from cost controls and reduced myeloma trial scope, and SG&A dropped 8% y/y to $28.5M. Net loss widened to $37.3M or $4.32/share (basic/diluted, anti-dilutive warrants excluded), versus $23.8M profit last year on one-time debt gain; diluted EPS reconciles to 8,620K shares. Cash and investments stood at $51.7M, with $240.8M total debt including $24.5M 2025 notes due October and $100M term loan to 2028 at SOFR+9.25%, revolver unavailable; FCF not disclosed in the 10-Q. No M&A or impairments noted. Competition from bispecifics and CAR-Ts in myeloma pressures XPOVIO uptake.
8-K
Karyopharm Q2 revenue up, trials advance
Karyopharm Therapeutics reported Q2 2025 total revenue of $37.9 million, with U.S. XPOVIO net product revenue rising 6% to $29.7 million versus last year, while license revenue dropped due to non-recurring items. The company nears completion of Phase 3 SENTRY trial enrollment in myelofibrosis, expecting top-line data in March 2026 amid promising early safety signals. Cash dwindled to $52.0 million; it's pursuing financing to extend runway past October 2025 notes maturity. Enrollment closes this week.
8-K
Workforce cuts amid financing hunt
Karyopharm disclosed confidential investor materials on July 11, 2025, after failed financing talks, while slashing its workforce by 20% to stretch cash amid going-concern doubts. Yet the firm presses on with its Phase 3 SENTRY trial in myelofibrosis, over 90% enrolled and eyeing top-line data in Q1 2026, touting selinexor's potential to boost spleen reduction and symptoms alongside ruxolitinib. Q1 net product revenue hit $21.1M, down from $26.0M due to $5M in returns, but demand grew 5%. No deal in sight.
APTOF
Aptose Biosciences. Inc.
1.25-0.01
COEP
Coeptis Therapeutics Holdings,
14.96-0.28
EXEL
Exelixis, Inc.
39.43-0.65
IOVA
Iovance Biotherapeutics, Inc.
2.00-0.19
KROS
Keros Therapeutics, Inc.
15.04-0.14
KURA
Kura Oncology, Inc.
10.62+0.36
LGND
Ligand Pharmaceuticals Incorpor
184.52-4.35
LPTX
Leap Therapeutics, Inc.
0.48-0.06
NVCT
Nuvectis Pharma, Inc.
6.77+0.34
SRPT
Sarepta Therapeutics, Inc.
23.25-0.20